Popular Posts

Saturday, 12 May 2018

Intas Pharma Walk In Interview For Quality Control, Production At 29 and 30 May @ Indore

Intas profile: Core competency across biosimilar and plasma derived products makes Intas’ Biologics Business Unit one of its fastest growing franchise. Keeping patient’s welfare and wellbeing at the forefront, since the year 2000 it has been developing bio-therapeutics that meet the highest quality standards, and making them available at affordable prices.
Leveraging its R&D strengths and state-of-the-art manufacturing facilities, Intas’ Biologics BU has been focused on developing high quality recombinant DNA protein (rDNA) products and plasma derived products to address unmet medical needs across various therapeutics areas such as Oncology (Cancer), Auto-Immune, Ophthalmology, Nephrology, and Plasma derived product based therapies.
Intas Pharma Walk In Interview For Quality Control, Production  At 29 and 30 May
Intas’ R&D capabilities and a pool of Scientists from world class institutes across the globe, coupled with cutting edge technology platform and know-how has made it possible to build a robust yet niche product portfolio consist of 11 commercialized products, 8 rDNA products including 1 monoclonal antibody, and 3 plasma derived products. In addition the company has as on date 12 products in its pipeline. In addition several products are exported to many countries under various distribution and licensing agreements.